Related by context. All words. (Click for frequent words.) 77 CRLX# 74 fosbretabulin 74 pharmacokinetic PK study 74 preclinically 73 vivo preclinical 73 vivo efficacy 72 histone deacetylase inhibitor 72 Phase 1a clinical 72 ENMD # 72 nonclinical studies 72 favorable pharmacokinetic profile 72 Onconase 72 mertansine 72 demonstrated antitumor activity 72 tolerability profiles 71 pharmacodynamic PD 71 trodusquemine 71 neratinib 71 pharmacokinetics PK 71 vidofludimus 71 liposomal formulation 71 Kahalalide F 71 preclinical pharmacokinetic 71 Zybrestat 71 NP2 Enkephalin 71 pharmacodynamic properties 71 GLP toxicology studies 71 Phase Ib clinical 71 Carfilzomib 71 pharmacokinetic pharmacodynamic 70 Phase Ib study 70 CCX# 70 Phase 1b clinical trials 70 preclinical pharmacology 70 Archexin 70 solithromycin 70 indibulin 70 preclinical studies 70 trastuzumab DM1 T DM1 70 rxRNA 70 Factor VIIa 70 Azedra 70 pharmacokinetic PK 70 Sym# 70 oral prodrug 70 preclinical 70 depsipeptide 70 HCV protease inhibitors 70 PSMA ADC 70 pharmacokinetic studies 70 trastuzumab emtansine T DM1 70 PEG SN# 69 JAK inhibitor 69 Preclinical studies 69 PSN# [002] 69 vitro experiments 69 MGN# 69 novel peptide 69 Prodarsan ® 69 Guanilib 69 Aplidin 69 Deforolimus 69 HQK 69 OMP #M# 69 Phase Ib II 69 davunetide intranasal AL 69 pharmacodynamic markers 69 histone deacetylase HDAC inhibitor 69 vivo validation 69 Phase IIb III 69 HuMax EGFr 69 immunotherapeutic vaccine 69 Multimeric 69 Hsp# Inhibitor 69 cMET 69 pharmacodynamic profiles 69 proteasome inhibitor 69 EGS# 69 Bendavia 69 PEGylated interferon 68 cannabinor 68 HuMax CD#b 68 MORAb 68 anti CD3 68 GRNCM1 68 preclinical toxicology 68 Pharmacokinetics PK 68 vinca alkaloid 68 PDE4 inhibitor 68 riociguat 68 novel histone deacetylase 68 phase IIa clinical 68 radezolid 68 Xanafide 68 BrachySil TM 68 CGEN # 68 pan HDAC inhibitor 68 darinaparsin ZIO 68 JAK2 inhibitor 68 OvaRex R 68 viral kinetics 68 BAL# [002] 68 NOX E# 68 PI3K/Akt pathway inhibitor 68 CBLC# 68 thorough QT 68 YONDELIS R 68 vascular disrupting agents 68 pharmacokinetic characteristics 68 IMA# 68 Anticalin ® 68 ganetespib 68 Cloretazine ® 68 Zalypsis 68 DXL# 68 Tarceva TM 68 PD LID 68 delafloxacin 68 Androxal TM 68 MAGE A3 ASCI 68 pain palliation 68 pharmacodynamic parameters 68 potent antitumor activity 68 peptide conjugated 68 seliciclib CYC# 68 Trofex 68 human microdosing 67 RGB # 67 huN# DM1 67 Zoraxel 67 teriflunomide 67 Solorel TM 67 ART# 67 HDL Selective Delipidation 67 multicenter Phase II 67 Omacetaxine 67 AKT inhibitor 67 volociximab 67 alvespimycin 67 ORMD 67 Apoptone 67 LymphoStat B TM 67 Anticalins ® 67 PHX# 67 bortezomib Velcade 67 KRN# 67 ON #.Na 67 vitro cytotoxicity 67 vascular disrupting agent 67 GLYX 67 tolerability pharmacokinetics 67 xenograft models 67 Phase Ia 67 PROSTVAC TM 67 Presents Preclinical Data 67 isoform selective 67 OHR/AVR# 67 trastuzumab DM1 67 Spiegelmer ® 67 Aflibercept 67 Valortim R 67 Antiviral Activity 67 R roscovitine 67 Afatinib 67 INCB# [001] 67 therapeutic monoclonal antibody 67 Vascugel ® 67 iSONEP 67 investigational humanized monoclonal antibody 67 Safinamide 67 midstage clinical 67 Zemplar Capsules 67 novel VDA molecule 67 RAV# 67 phase IIa 67 phase IIb study 67 phase Ib 67 Preclinical Study 67 AAG geldanamycin analog 67 neuroprotective properties 67 Exherin TM 67 vitro studies 67 selective androgen receptor modulator 67 RE SURGE 67 p# inhibitor 67 candidate CRLX# 67 HGS ETR2 67 CTAP# Capsules 67 CaPre TM 67 tubulin inhibitor 67 TAKSTA 67 phase IIb III 67 radiation dosimetry 67 PhG alpha 1 67 huC# DM4 67 Prodarsan R 67 PDE# inhibitors 67 phase IIIb 67 telomerase inhibitor drug 67 cyclophilin inhibitors 67 tkRNAi 67 Squalamine 67 inhibitor RG# 67 maximally tolerated dose 67 BrachySil 67 MEK inhibitor 67 INGN 67 Traficet EN 67 orally bioavailable 67 Pharmacodynamic 67 Vaxfectin R adjuvant 67 IIa trials 67 Anavex #-# 67 PRT# 67 OvaRex MAb 67 NOD mouse 67 YONDELIS 67 Cardiotoxicity 67 Capesaris 67 CD# CEA 67 Phase #b/#a trial 67 EKC Cide 67 safety tolerability pharmacokinetic 67 Quinamed 67 Novolimus 66 torezolid phosphate 66 Phase IIA 66 vivo toxicology 66 ONCONASE R 66 Panzem 66 phase 2a 66 TBC# 66 Initiated Phase 66 pharmacodynamic effects 66 Pharmacokinetic PK 66 flavopiridol 66 MGd 66 OncoVex 66 BRAF inhibitor 66 CCR5 antagonist 66 Phase IIB 66 CG# [003] 66 ocular formulation 66 metaglidasen 66 antisense inhibitors 66 CINQUIL 66 AEZS 66 crizotinib PF # 66 Phase IIb clinical trials 66 Valortim ® 66 NEUVENGE 66 targeted radiotherapeutic 66 Rigel R# 66 telomerase therapeutic 66 Reports Preclinical Data 66 antibody MAb 66 rBChE 66 CEQ# 66 Zenvia Phase III 66 lexidronam injection 66 Exelixis compounds 66 Phase #b/#a clinical 66 TRO# 66 ATL# [002] 66 enzastaurin 66 pharmacokinetics pharmacodynamics 66 elacytarabine 66 Cloretazine 66 OncoVEX 66 ESBA# 66 antitumoral 66 retapamulin 66 GRN# 66 systemically administered 66 iroxanadine 66 pharmacokinetic parameters 66 EXPAREL ™ 66 TRV# [001] 66 Angiolix 66 clevidipine 66 humanized monoclonal 66 GMX# 66 DermaVir Patch 66 anti amnesic 66 ATL# [001] 66 GRNVAC1 66 mGluR2 NAM 66 bazedoxifene conjugated estrogens 66 Solazed TM 66 Thiovir 66 R#/MEM # 66 NP2 66 HGS# 66 CYT# potent vascular disrupting 66 NEUGENE R 66 orally administered inhibitor 66 viral kinetic 66 immune modulating 66 PS# [001] 66 H#N# VLP vaccine 66 Phase 1b clinical 66 Phase 2a clinical 66 CORT # 66 Phase 2b clinical trials 66 Sphingomab 66 Anticalin R 66 alagebrium 66 UPLYSO 66 ALN TTR# 66 thalidomide Thalomid 66 placebo controlled clinical 66 GAMMAGARD 66 Pimavanserin 66 ADVANCE PD 66 Symadex 66 MEK inhibitors 66 pertuzumab 66 pharmacodynamic profile 66 PRTX 66 Iloperidone 66 BNC# 66 Vaxfectin 66 Phase 1b trial 66 prucalopride 66 DASISION 66 pomalidomide 66 Virulizin ® 66 SCH # 66 PXD# 66 Tarvacin TM 66 PKC# 66 TransVax ™ 66 Telatinib 66 multicenter clinical trials 66 Panzem R NCD 66 Cloretazine R 66 CA4P 66 Phase #b/#a 66 Phase 1a 66 Anticalins R 66 nanoviricides 66 Tyrima 66 uricase 66 Protectan CBLB# 66 dose escalation clinical 66 OXi# 66 Phase IIIb clinical 66 Systemic Delivery 66 CRMD# 66 urocortin 2 66 EndoTAG TM 66 ospemifene 66 LT NS# 66 reslizumab 66 NEUMUNE 66 PROCHYMAL 66 hematological tumors 66 Nonclinical 66 antisense inhibitor 65 Aurora Kinase 65 liposomal doxorubicin 65 phase IIb clinical 65 anti fibrotic 65 masitinib 65 NB S# strontium malonate 65 Vascugel R 65 Lisofylline LSF 65 non nucleoside HCV 65 potent antiproliferative 65 Bezielle 65 ZACTIMA 65 Phase Ib clinical trials 65 TÎ ² 4 65 GLPG# 65 pharmacokinetic 65 Xelox 65 antiangiogenic agents 65 pharmacokinetic PK profile 65 Thorough QT 65 motesanib diphosphate 65 Mipomersen 65 abstracts summarizing 65 efficacy tolerability 65 DiLA2 65 brivaracetam 65 Tanespimycin 65 Triapine 65 siRNAs targeting 65 nanopharmaceutical 65 HDL Mimetic Peptide 65 inhaled AAT 65 Phase IIa trial 65 oral picoplatin 65 genomic biomarker 65 BioVant 65 nucleotide analog 65 anticoagulant reversing agent 65 vitro ADME 65 liposome formulation 65 Phase IIa trials 65 efficacy 65 Meta analyzes 65 Hyphanox 65 resolvin 65 Valortim 65 pDNA vaccine 65 galiximab 65 Lenocta 65 DEB# 65 including eniluracil ADH 65 ADAGIO study 65 targeted antifolate 65 immune modulatory 65 GelSite polymer 65 Vaxfectin R 65 murine models 65 Tß4 65 NEUGENE 65 Omacetaxine mepesuccinate 65 Imprime PGG 65 TKM ApoB 65 Immunogenicity 65 CLORETAZINE TM VNP#M 65 Triapine R 65 SNALP technology 65 CIMZIA ™ 65 stated Michelle Berrey 65 HDAC Inhibitor 65 potency selectivity 65 hyaluronidase enzyme 65 Myocet 65 Alocrest 65 multitargeted 65 farletuzumab 65 Darinaparsin 65 orally inhaled migraine 65 Tesmilifene 65 PORxin TM 65 JVRS 65 Vitaxin 65 Phase 2a trial 65 receptor tyrosine kinase inhibitor 65 EGFR HER2 65 dose escalation Phase 65 dose proportionality 65 PLK1 SNALP 65 busulfan 65 Thiarabine 65 Oral NKTR 65 HCV NS5B polymerase 65 fidaxomicin Phase 3 65 demonstrated clinically meaningful 65 IND submission 65 SinuNase ™ 65 mTOR inhibitors 65 Curaxin CBLC# 65 tumorigenicity 65 JAK inhibitors 65 encapsulates siRNAs 65 clinical pharmacology studies 65 relapsed MM 65 Enzastaurin 65 Pharmacokinetic 65 BiTE antibody MT# 65 Cethrin R 65 TLR9 agonist 65 Blinatumomab 65 TASKi3 65 SABCS 65 TLR8 agonist 65 TG# [003] 65 PK PD 65 Tumor Response 65 midstage trials 65 HIF PH inhibitors 65 AEG# 65 targeting CD# 65 GSK# [002] 65 MCSP respectively 65 tipifarnib 65 PORxin TM platforms 65 non nucleoside inhibitor 65 phosphatidylserine PS targeting 65 Phase 2a clinical trials 65 TriGrid 65 GW# [003] 65 DCCR 65 oral renin inhibitor 65 topically administered 65 tumor xenograft models 65 evaluating tivozanib 65 PI3K/mTOR 65 ISIS # 65 HuCAL antibodies 65 INS# [001] 65 histamine dihydrochloride 65 multicenter Phase III 65 VeriStrat 65 oral ghrelin agonist 65 APOPTONE 65 Protexia R 65 vitro dissolution 65 cyclophilin inhibitor 65 trastuzumab Herceptin R 65 AEGR 65 Panzem R 65 Pharmacokinetic studies 65 PI3K inhibitor 65 velafermin 65 ongoing Phase 1b 65 ANAVEX #-# [001] 65 LB# [003] 65 erythropoietic 65 HIF PHI 65 #th Annual Interscience 65 varespladib 65 Valortim TM 65 BrachySil ™ 65 Estrogen Receptor 65 CINTREDEKIN BESUDOTOX 65 VNP#M 65 CCR9 antagonist 65 KSP inhibitor 65 Elagolix 65 NSABP B 65 EOquin TM 64 oral FTY# 64 Teriflunomide 64 PrevOnco 64 protein kinase inhibitor 64 HSP# inhibitor 64 cathepsin K inhibitor 64 vivo preclinical studies 64 Bruton tyrosine kinase Btk 64 Aplidin R 64 torezolid 64 non nucleoside 64 potently inhibited 64 RNAi Therapeutic 64 radiolabeled 64 entinostat 64 ToGA 64 Soliris eculizumab 64 mouse xenograft models 64 obatoclax 64 paclitaxel poliglumex 64 predictive toxicology 64 axitinib 64 Dalbavancin 64 acetonide FA 64 cytokine refractory 64 Proxinium TM 64 EndoTAG TM -1 64 antimitotic 64 sulodexide 64 Azedra TM 64 analgesic efficacy 64 OncoVEX GM CSF 64 RE COVER 64 aurora kinase 64 Temsirolimus 64 kinase profiling 64 SRT# [003] 64 cilengitide 64 Muraglitazar 64 SAR# [004] 64 murine model 64 Phase IIa clinical 64 novel immunotherapeutic 64 MVA BN R 64 AZX# 64 mg kg BID 64 pharmacodynamics 64 intranasal formulation 64 selective modulator 64 JAK2 inhibitors 64 kidney urologic 64 pharmacodynamic endpoints 64 preclinical models 64 A3 adenosine receptor 64 #F FDG PET 64 orally dosed 64 HepDirect prodrug 64 antiangiogenic agent 64 novel oral anticoagulant 64 ZFP Therapeutic 64 triphendiol 64 OX1 64 Degarelix 64 Dacogen injection 64 sd rxRNA 64 cynomolgus monkeys 64 cleavable linker 64 Panzem NCD 64 AIR# [001] 64 CCR5 mAb 64 Ceflatonin 64 OvaRex ® MAb 64 biodistribution 64 EDEMA3 trial 64 XmAb# 64 vivo potency 64 ARIKACE ™ 64 Valdoxan 64 eTag assays 64 DermaVir 64 APEX PD 64 XL# SAR# 64 prokinetic agent 64 pharmacodynamic 64 acyclovir Lauriad R 64 Synavive 64 Alequel ™ 64 Presents Preclinical 64 Protexia ® 64 DDP# 64 delipidation 64 CHAMPION PCI 64 erlotinib Tarceva ® 64 oral PTH 64 EGEN 64 FK# 64 pharmacokinetic profiles 64 Phase #/#a 64 acyclovir Lauriad ® 64 MEK inhibitor RDEA# 64 AACR NCI EORTC 64 Pharmacokinetic parameters 64 radiation sensitizer 64 lead Aganocide compound 64 metabolite identification 64 deforolimus 64 cediranib 64 Geron telomerase inhibitor 64 Radilex 64 P#X# antagonist 64 immatics 64 LibiGel Phase III 64 predictive biomarker 64 Pemetrexed 64 antiviral efficacy 64 small molecule tyrosine 64 AVERROES 64 Solulin 64 alemtuzumab MS 64 Inhalation Solution 64 evaluating REVLIMID 64 bactericidal activity 64 MEND CABG 64 antitumor activity 64 Completes Patient Enrollment 64 Azedra ™ 64 mitogen activated ERK kinase 64 Pertuzumab 64 trastuzumab Herceptin ® 64 epigenetic therapies 64 Nanobodies ® 64 Zysolin TM 64 Preclinical Efficacy 64 anti CD3 antibody 64 DB# [003] 64 Tyrosine Kinase Inhibitor 64 Anthim 64 LC#m# 64 anti leukemic 64 Angiocept 64 compound AEZS 64 omacetaxine mepesuccinate 64 ZK EPO 64 Romidepsin 64 Phase #/#a trial 64 NeuroSTAT ® 64 2 inhibitor CYT# 64 Kevetrin ™ 64 selective kinase inhibitor 64 BRIM3 64 #I TM# 64 antiviral potency 64 Aganocide ® 64 CardioPET 64 investigational protease inhibitor 64 gefitinib Iressa 64 oxazolidinone 64 Ampligen ® 64 lomitapide 64 selective orally bioavailable 64 potent cytotoxic 64 GVAX ® 64 investigational monoclonal antibody 64 ATL/TV# 64 CDK inhibitor 64 Immunotherapeutic 64 perifosine KRX 64 oral antiviral 64 Vaxfectin TM 64 ELACYT 64 histone deacetylase HDAC 64 ZYBRESTAT fosbretabulin 64 mTOR inhibition 64 antifibrotic 64 miRview ™ squamous 64 elotuzumab 64 bevacizumab Avastin ® 64 LUX Lung 64 somatostatin analogue 64 phase IIb 64 sorafenib Nexavar 64 NO# [002] 64 Proellex TM 64 phase Ib clinical 64 SUCCEED trial 64 INT# [002] 64 PANVAC VF 64 PEG IFN 64 small molecule activators 64 mda 7 64 acadesine 64 immune modulation 64 radiolabeled monoclonal antibody 64 TELINTRA 64 vemurafenib 64 antitumor effects 64 QLT# 64 Solorel 64 tanespimycin 64 XL# inhibits 64 Ozarelix 64 Pivotal Phase III 64 Cerashield 64 PREOS R 64 favorable pharmacokinetic 64 oral JAK1 64 antitumor efficacy 64 humanized monoclonal antibodies 64 Tesetaxel 64 confirmatory clinical 64 NEUGENE antisense 64 SAR# [002] 64 basal bolus regimen 64 FOLOTYN ® 64 VersaFilm 64 ThermoDox ® clinical 64 rhLF 64 immuno therapeutic 64 TPI ASM8 64 Achieves Primary Endpoint 64 XL# XL# 64 plasma pharmacokinetics 64 RhuDex R 64 Interferon Gamma 64 oral bioavailability 64 ruxolitinib 64 S/GSK# 64 ProSavin 64 metaanalysis 64 Ocrelizumab 64 Onrigin 64 Pyridorin 64 rALLy clinical trial 64 epoetin alpha 64 antisense inhibition 64 pharmacokinetic pharmacodynamic PK PD 64 DPX Survivac 64 REG2 64 DNA methylation markers 64 anti angiogenic agent 64 retaspimycin 63 interferon gamma 1b 63 EP #R 63 cartilage regeneration 63 antiangiogenic activity 63 TKB# 63 LUMINATE 63 PDX pralatrexate 63 Golimumab 63 humanised monoclonal antibody 63 Phase III ADT 63 Aurora kinase inhibitors 63 CCR1 63 Adnectin 63 GRAVITAS trial 63 anticancer activity 63 Vernakalant 63 hGH CTP 63 alpha antagonist 63 PROactive study 63 SUTENT ® 63 Acute Ischemic Stroke 63 ALN VSP 63 Btk inhibitor 63 intravenous dosing 63 Bucindolol 63 Prostate AdenoCarcinoma Treatment 63 STRIDE PD 63 angiotensin analog 63 Triolex 63 telomerase inhibitor 63 virus HCV protease inhibitor 63 Kinase Inhibitor 63 Posiphen 63 phase IIb trial 63 dacetuzumab 63 intranasal delivery 63 Lpathomab 63 RhuDex ® 63 RezularTM 63 Hedgehog inhibitor 63 Trodusquemine 63 CA9 SCAN 63 Prodarsan 63 biodistribution studies 63 Preclinical studies suggest 63 AMD# [003] 63 Spiegelmer 63 GRN#L 63 next generation URAT1 63 Antitumor Activity 63 Aclidinium 63 Chemophase 63 Combination REOLYSIN R 63 rALLy trial 63 PROSTASCINT R 63 TRANSFORMS 63 cellular immunotherapy 63 TRX1 63 rNAPc2 63 TLR antagonists 63 vivo 63 forodesine 63 Zenvia ™ 63 Erimos 63 genotoxicity 63 Phase 2b Clinical Trial 63 Myolimus 63 REG1 63 microtubule inhibitor 63 multicenter randomized placebo controlled 63 molecular biomarkers 63 oral rivaroxaban 63 novel therapeutic antibodies 63 p# biomarker 63 Tarvacin 63 sodium thiosulfate STS 63 TAXUS ATLAS 63 Hedgehog Pathway Inhibitor 63 pharmacodynamics PD 63 PrevOnco ™ 63 TriRima 63 Aurexis 63 Initiates Clinical 63 pharmacokinetic equivalence 63 R#/MEM 63 multicenter trials 63 Clinical Trial Results 63 investigational pan BCR 63 Onalta 63 cobiprostone 63 florbetaben 63 highly selective inhibitor 63 therapeutic mAbs 63 ibudilast 63 pemetrexed Alimta 63 selective estrogen receptor modulator 63 SNT MC# 63 potent anticancer 63 CCR9 63 ChronVac C R 63 AMPK activators 63 intravesical instillation 63 vascular disrupting 63 Phase Ib 63 Annamycin 63 aerosolized KL4 surfactant 63 XOMA 3AB 63 Phase III Clinical Trials 63 receptor inhibitor 63 HIV integrase inhibitor 63 Phase 2a 63 vitro potency 63 AMPAKINE CX# 63 ataluren 63 CANCIDAS 63 Sipuleucel T 63 lumiliximab 63 ELND-#/AZD-# 63 STEDESA 63 ANG# 63 mapatumumab 63 MET amplification 63 biostatistical analysis 63 anti CD# antibodies 63 angiogenesis inhibitor 63 randomized multicenter trial 63 Allovectin 7 63 Personalized Immunotherapy 63 direct thrombin inhibitors 63 Alfacell proprietary ribonuclease 63 LibiGel ® 63 ZFN modified 63 Potent Antiviral Activity 63 GFT# 63 FOLFOX6 chemotherapy regimen 63 randomized Phase 2b 63 BiTE R 63 nalbuphine ER 63 IRX 2 63 Litx 63 gallium containing 63 ZOLINZA 63 somatostatin analog 63 Cloretazine R VNP#M 63 Nanobody ® 63 mechanistic insights 63 tolerability profile 63 Epidermal Growth Factor Receptor 63 Pre RELAX AHF 63 lintuzumab 63 afamelanotide 63 aurora kinase inhibitor 63 ALN TTR 63 LAB CGRP 63 chimeric antibody 63 metabolomic profiling 63 Amrubicin 63 Radezolid 63 azilsartan medoxomil 63 Phase 2b study 63 PNT# 63 Neugene 63 Catena ® 63 Vidaza azacitidine 63 Cytochrome P# 63 SPIRIT FIRST 63 trabectedin 63 Saforis 63 ORENCIA R 63 cationic lipid 63 pramlintide metreleptin combination 63 bosutinib 63 ganaxolone 63 Homspera TM 63 CB1 antagonists 63 virosome 63 Intravitreal 63 midstage clinical trials 63 QTinno 63 cariprazine 63 MVA MUC1 IL2 63 Prospective Randomized 63 fluoropyrimidine 63 CR# vcMMAE 63 Multiple Ascending Dose 63 Xcytrin R 63 CIMZIA TM certolizumab pegol 63 Sphingomab TM 63 II Clinical Trial 63 RE LY ® 63 Nasdaq IDRA today 63 BRILINTA 63 OLYMPIA registry 63 Civacir 63 NOD SCID mice 63 melphalan prednisone 63 Phase 1b 63 thetreatment 63 OMAPRO ™ 63 hepatitis B vaccine Heplisav 63 RECORD1 63 anticancer compound 63 BAL# [001] 63 multi kinase inhibitor 63 Maribavir 63 Tasimelteon 63 Phase IIIb 63 Tezampanel 63 TLK# 63 DepoVax 63 Initiate Clinical Trial 63 Cardiomyocytes 63 taxane resistant 63 Perforomist ™ Inhalation Solution 63 Perifosine 63 ImmunoVEX HSV2 63 HCV SPRINT 63 Plicera 63 plasma kallikrein inhibitor 63 SMT C# 63 Arimoclomol 63 TOLAMBA 63 TLR agonists 63 AtherOx 63 VitiGam 63 Neuradiab 63 BMS# 63 RH1 63 VIR# 63 synthetic retinoid 63 Liposomal 63 GAP #B#